-

SHAREHOLDER ALERT: Robbins LLP Announces that Oatly Group AB (OTLY) is Being Sued for Misleading Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action has been filed on behalf of all purchasers of American Depository Shares ("ADSs") of Oatly Group AB (NASDAQ: OTLY) between May 20, 2021 and July 15, 2021, for violations of the Securities Exchange Act of 1934. Oatly describes itself as the world's original and largest oatmilk company.

If you suffered a loss due to Oatly Group AB's misconduct, click here.

Oatly Group AB (OTLY) Made Misleading Statements in its Registration Statement in Connection with its Initial Public Offering

According to the complaint, Oatly held its initial public offering ("IPO") on May 20, 2021, raising $1.4 billion for the Company. The Registration Statement in support of the IPO overinflated its gross margins, revenue, capital expenditure, and market share financial metrics; overstated its sustainability practices and impact; and, exaggerated its growth in China. On July 14, 2021, before the markets opened, short seller Spruce Point Capital Management issued a 124-page report noting a number of improprieties at Oatly, including improper accounting practices and greenwashing, among other issues. Of particular note is that Oatly estimated 2018 U.S. revenue to be $12 million, while Nielsen and Umgas Magazine "reported that Oatly's net U.S. sales were just $6 million in 2018." Over the next two days, various media articles picked up and commented on the report. On this news, the price of Oatly ADSs fell 8.8% over two trading days, to close at $19.48 on July 14, 2021.

If you purchased shares of Oatly Group AB (OTLY) between May 20, 2021 and July 15, 2021, you have until September 24, 2021, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Oatly Group AB settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:OTLY

Release Versions
$Cashtags

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Robbins LLP Informs Investors of the Soleno Therapeutics, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Soleno Therapeutics (NASDAQ: SLNO) common stock between March 26, 2025 and November 4, 2025. Soleno is a pharmaceutical company focused on developing therapies for rare diseases. The Company’s only commercial product is diazoxide choline extended-release tablets (“DCCR”) for the treatment of hyperphagia in individuals afflicted with Prader-Wil...

Investor Notice: Robbins LLP Informs Investors of the Eos Energy Enterprises, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Eos Energy Enterprises, Inc. (NASDAQ: EOSE) securities between November 5, 2025 and February 26, 2026. Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems intended for utility-scale commercial and industrial applications. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call...

Investor Notice: Robbins LLP Informs Investors of the Nektar Therapeutics Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin (a/k/a REZPEG or NKTR-358), a n...
Back to Newsroom